It is hard to forecast. But if the annual US market for copaxone is ~3 billion currently, even if that shrinks to half (~1.5 billion) and Teva maintains 60% of it (900 million), that leaves ~600 million for MYL and Sandoz/MNTA to split. MNTA's share from that 300 million, assuming 70% margin, is still 105 million annually, which would put them at break even or a slight profit.
Market Data 
Markets 
AI
